SARS-CoV-2 seroprevalence in HIV+ individuals in Germany

• Conditions: B24; Unspecified human immunodeficiency virus [HIV] disease

• Registration Number: DRKS00028631
• Lead Sponsor: niversitätsklinikum Essen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1339

Inclusion Criteria

Chronic HIV infection

Exclusion Criteria

Vaccination against SARS-CoV-2

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
anti-SARS-CoV-2 spike IgM and IgG levels determined by ELISA

Secondary Outcome Measures

Name	Time	Method
Statistical analysis of possible relationships between the measured antibody responses against SARS-CoV-2 and<br><br>1. Basic patient information<br>2. Clinical parameters<br>3. Antiretroviral treatments<br>4. Socioeconomic factors